Back to top

NeoGenomics launches FDA-approved PTEN IHC prostate Cancer ompanion diagnostic

NeoGenomics (NEO) announced the launch of PTEN IHC CDx, the first immunohistochemistry companion diagnostic test approved by the FDA for patients w...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

NeoGenomics, Inc. (NEO)